Skip to main content
Genor Biopharma Holdings Limited logo

Genor Biopharma Holdings Limited — Investor Relations & Filings

Ticker · 6998 LEI · 254900QMR54NB8I3GG47 HKEX Manufacturing
Open in API
Filings indexed 419 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 6998

About Genor Biopharma Holdings Limited

https://www.eddingpharm.com

Genor Biopharma Holdings Limited is an innovation-driven biopharmaceutical company focused on the discovery, research, development, and commercialization of human biological pharmaceutical products. The company primarily targets oncology and autoimmune diseases, with an expanding pipeline covering cardiovascular, respiratory, and anti-infective fields. Genor operates a full value chain encompassing R&D, world-class manufacturing, and a robust commercialization network. A key strategic element is the integration of technology and AI into its drug development platform to accelerate clinical-stage therapies. While rooted in China, the company actively pursues global cooperation, in-licensing, and the development of commercial capabilities in overseas mainstream markets to deliver innovative treatments to patients globally.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - LATEST UPDATE ON COOPERATION WITH CANDID THERAPEUTICS
Regulatory Filings
2026-05-04 English
Next Day Disclosure Return
Regulatory Filings
2026-04-30 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is an HKEx ‘‘Next Day Disclosure Return’’ (Form FF305) detailing changes in issued shares and treasury shares, including a repurchase of 1,000,000 shares held as treasury shares under Main Board/GEM rules. It provides complete repurchase report data (dates, number of shares repurchased, prices, aggregate amounts) and confirmations by the issuer’s officers. This is not a general Annual or Interim Report, nor a simple announcement of publication. It specifically reports on the company's own share repurchase activity, matching the definition of a Transaction in Own Shares (code POS).
2026-04-29 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Stock Exchange rules, detailing changes in issued shares and treasury shares, including share repurchases and on-market sales of treasury shares. This is a direct company report of buying back its own shares, matching the definition of “Transaction in Own Shares” (POS).
2026-04-28 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (FF305) filed under Hong Kong Main Board/GEM Rules detailing changes in issued and treasury shares, including share repurchases on-market, treasury share holdings, and confirmations under Rule 13.25A/10.06. It is a report of the company buying back its own shares, fitting the definition of Transaction in Own Shares (share repurchase/issuance).
2026-04-27 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a ‘‘Next Day Disclosure Return’’ (Form FF305) filed under Hong Kong Main Board/GEM rules, detailing changes in issued shares/treasury shares and a share repurchase transaction on‐market. It is a report of the company buying back its own shares. This corresponds exactly to the “Transaction in Own Shares” category (POS).
2026-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.